Global Antibiotics Partnering Terms and Agreements 2010 to 2017

Publisher Name :
Date: 01-Apr-2017
No. of pages: 222
Inquire Before Buying

Summary

The Global Antibiotics Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the antibiotic partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Antibiotics Partnering Terms and Agreements 2010 to 2017 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in antibiotics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Antibiotics partnering contract documents

Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

Antibiotics

Aminoglycosides

Cephalosporin

Clindamycin

Macrolides

Penicillin

Quinolones

Sulfonamides

Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2017 includes:

Trends in antibiotics dealmaking in the biopharma industry since 2010

Analysis of antibiotics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life antibiotics deals

Access to over 200 antibiotics deal records and contract documents where available

The leading antibody deals by value since 2010

Most active antibiotics dealmakers since 2010

The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2017, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Antibiotics Partnering Terms and Agreements 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of antibiotics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of antibiotics agreements with numerous real life case studies

Comprehensive access to over 200 antibiotics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available

Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus

Identify leading antibiotics deals by value since 2010

Identify the most active antibiotics dealmakers since 2010

Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies

Insight into the terms included in a antibiotics agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Antibiotics Partnering Terms and Agreements 2010 to 2017

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking

2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Most active antibiotics dealmakers
2.4. Antibiotics partnering by deal type
2.5. Antibiotics partnering by therapy area
2.6. Antibiotics partnering by industry sector
2.7. Deal terms for antibiotics partnering
2.7.1 Antibiotics partnering headline values
2.7.2 Antibiotics deal upfront payments
2.7.3 Antibiotics deal milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of an antibiotics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading antibiotics deals

3.1. Introduction
3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers

4.1. Introduction
4.2. Most active antibiotics dealmakers
4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory

5.1. Introduction
5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type

Antibiotics
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Metronidazole
Penicillin
Quinolones
Tetracycline

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Antibiotics deals by company A-Z
Appendix 2 - Antibiotics deals by stage of development
Appendix 3 - Antibiotics deals by deal type
Appendix 4 - Antibiotics deals by therapy area
Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Antibiotics partnering since 2010
Figure 2: Active antibiotics dealmaking activity sincce 2010
Figure 3: Antibiotics partnering by deal type since 2010
Figure 4: Antibiotics partnering by disease type since 2010
Figure 5: Antibiotics partnering by industry sector since 2010
Figure 6: Antibiotics deals with a headline value
Figure 7: Antibiotics deals with an upfront value
Figure 8: Antibiotics deals with a milestone value
Figure 9: Antibiotics deals with a royalty rate value
Figure 10: Top antibiotics deals by value since 2010
Figure 11: Most active antibiotics dealmakers since 2010
Figure 12: Antibiotics partnering by technology type since 2010
Figure 13: Online partnering resources
Figure 14: Forthcoming partnering events
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 52
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2017, provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) (Infectious Disease) pipeline landscape.Burkholderia pseudomallei are a gram negative, bipolar, aerobic, motile rod-shaped soil dwelling bacterium. The bacterium can infect both animals and humans through direct contact via inhalation, ingestion, or open ......
  • Escherichia coli Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 152
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated......
  • Tularaemia - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H1 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal ......
  • Diphtheria - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever ......
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 79
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2017, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of V......
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 374
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as commun......
  • Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 40
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline Review, H1 2017, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections (Infectious Disease) pipeline landscape.Methicillin-Susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually cause skin infections, but can also cause pneumonia, and other seriou......
  • Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 97
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.......
  • Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017
    Published: 23-May-2017        Price: US 2000 Onwards        Pages: 164
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2017, provides an overview of the Cytomegalovirus (HHV-5) Infections (Infectious Disease) pipeline landscape.Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The pr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs